This site has moved to www.BiotechBlog.com

Welcome to the inaugural Carnival of Biotechnology. This roundup of the best blogs on biotechnology brings together the best posts covering the industry.

This week’s carnival is hosted here at Biotechblog.com. The next post will be at About.com Biotechnology.

For more information about the Carnival of Biotechnology, see the Carnival’s homepage.

Without further ado, here’s this week’s entry:

Finance and business development

Ben McClure at at Investopedia has put together a sample case of Using DCF In Biotech Valuation. This excellent tutorial provides a clear example of how to apply this commonly used biotech valuation tool.

Politics

The Drugwonks aren’t bashful in their critique of price controls. In ‘Of Barn Doors and Horses‘ they bemoan the ineffecient circle of impeding vaccine development through price controls, tort liabilities and other factors while providing government incentives to foster the development of vaccines.
Regulation

In a trifecta of posts directed at reimportation, the Drugwonks explain that Counterfit Drugs are a Global Problem, imported drugs shouldn’t be used Because They’re Illegal and Unsafe and ask Who’s Next, given the dramatic increase in counterfit drugs seizures over the past decade.

See you next time at About.com Biotechnology.

The Carnival of Biotechnology is a regular roundup of the best blog posts on biotechnology. The carnival is guest-hosted by different sites, ensuring diversity in content and viewpoints. Check out the info page and submit your article or sign up to host the carnival.

This blog post and the ensuing discussion present an interesting and revealing dialogue on the practicality of creating an open marketplace for biotech patents; the benefits of open-licensing must be weighed against the high capital and time requirements for vetting and development.

HGS recently completed a $225 million factory to make products that still don’t exist…

‘Canadian’ pharmacies not actually in Canada…
An investigation conducted by the U.S. Food and Drug Administration found a significant percentage of drugs touted as Canadian and shipped from Internet pharmacy websites claiming to be Canadian were not actually from Canada.

Scripps Institute proposes new Florida site for biotech park
The California-based Scripps Research Institute has told Palm Beach County commissioners that it now prefers to build its planned biotechnology park at the Florida Atlantic campus in Jupiter, a decision that came two weeks after construction on the original site near the Everglades was halted.

Intellectual Property: Last chance for Europe’s biotech pioneers
With the US in regulatory limbo, Europe is winning the race to be the first regulated drugs market to approve generic copies of biotech drugs – despite the protests of the biotech pioneers who created them.

Financial Snapshot For September 2005 Reason To Smile

Overcoming Offshoring in Biotechnology
Offshoring labor to countries with cheaper labor and relaxed regulatory schemes has devastated industries such as textiles and manufacturing – and stands to do the same for much of biotechnology R&D. Read this essential series of articles to learn more about the potential and impacts of offshoring in biotechnology, and way to deal with this inevitability.